M&A Analysis: Bio-Techne enters Genomics market with $250M acquisition of Advanced Cell Diagnostics

Bio-Techne Corporation have agreed to acquire California-based molecular pathology company Advanced Cell Diagnostics for $250 million in cash plus additional potential milestone payments of up to $75M. The acquisition marks

Texcell acquisition of Vivo Science underscores the shifting Biopharma Contract Services landscape

Texcell, a French provider of biosafety contract services, recently acquired German company Vivo Science GmbH, a GLP/GMP compliant contract research test facility specialising in toxicology, immunology & virology in vivo

Thermo Fisher to Acquire FEI Company for $4.2B

Thermo Fisher Scientific have further cemented their reputation as a serial acquirer with the purchase of FEI Company for approximately $4.2B in cash. Oregon-based FEI Company are world leaders in

Further AgriBusiness Consolidation as Bayer Makes a $62B Bid for Monsanto

Last week German multinational Bayer put forward an all-cash $62B bid for American AgTech giant Monsanto, further emphasizing the unprecedented period of consolidation that the global AgriBusiness market is currently

Cell Therapy Ltd grants Japanese Licence for its Heart Regeneration Medicine to Daiichi Sankyo

Welsh stem cell company Cell Therapy Ltd. has granted Japanese drugmaker Daiichi Sankyo a license for Heartcel™, its promising cardiac regeneration medicine. Under the conditions of the deal, Daiichi Sankyo

Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for the company throughout 2016

Evolution Infographic: The Rise & Diversification of Biologics

For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and

To CRISPR or not to CRISPR: The Ongoing Ethical Debate Surrounding Embryonic Gene Editing

The UK’s Human Fertilisation and Embryology Authority (HFEA) has given the go-ahead for a select group of Francis Crick Institute researchers to edit the genomes of human embryos. The group,

Evolution Analysis: ACD Bio & Leica Biosystems Expand RNAscope Diagnostics Partnership

Advanced Cell Diagnostics and Leica Biosystems have announced a comprehensive partnership to develop and commercialise tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridisation (ISH) assays and Leica’s clinical

Evolution M&A Analysis: Thermo Fisher to Acquire Affymetrix for $1.3 billion

Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously approved by the boards

The Role of Metagenomic Analysis in Drug Development

In recent years Next Generation Sequencing instrumentation has become much more accurate, efficient and affordable, enabling researchers to collect, sequence and analyse genomes with increasing ease. Consequently researchers are developing

Evolution Analysis – Google, Sanofi, Novartis and the Race to Improve Diabetes Health Outcomes

On August 31, 2015 Google Life Sciences and French pharma giant Sanofi announced that the two companies will work together on new digital technology and tools for the treatment of

Evolution Announce Human Capital Partnership with Genomics Startup QuantiHealth

Evolution Global Talent Attraction recently signed a contract to provide human capital to newly formed company QuantiHealth in China. QuantiHealth was founded by Zhao Bowen, who was named as one

Arysta LifeScience announce exclusive commercial partnership at Plant Impact Investors Day

Evolution Global Talent Attraction were recently invited to crop enhancement company Plant Impact’s Investors Day at Rothamsted, where Plant Impact announced the commercial launch of BANZAI, a novel product that

Research Chemicals Leader Alfa Aesar to be acquired by Thermo Fisher Scientific

Thermo Fisher Scientific have signed a definitive agreement to acquire Alfa Aesar, a leading global manufacturer of research chemicals, for £256 million (approximately $405 million USD) in cash. Alfa Aesar’s